ICD Implantations in the Pediatric and Young Adult Population by Ten Harkel Arend DJ & Blom Nico A
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






ICD Implantations in the  
Pediatric and Young Adult Population 
Ten Harkel Arend DJ and Blom Nico A 
Leiden University Medical Center, Department of Pediatric Cardiology, Leiden,  
The Netherlands 
1. Introduction  
Large clinical trials in adult patients at risk for sudden cardiac death (SCD) have proven the 
efficacy of implantable cardioverter defibrillator (ICD) therapy for both secondary and 
primary prevention of SCD (Moss et al., 1996). In 1989, the first use of ICDs in young 
patients was reported (Kral et al., 1989). Since this initial report, ICD therapy has become 
increasingly important as a treatment approach in the pediatric population, despite the lack 
of randomized pediatric ICD studies. Nevertheless, children still present only 1% of all ICD 
recipients. The first large study of  ICD implantations in patients below the age of 20 years 
was reported by Silka et al in 1993 (Silka et al., 1993). Since then many retrospective cohorts 
describing the clinical outcome of pediatric ICD therapy have been published. (Eicken et al., 
2006; Ten Harkel et al., 2005; Heersche et al., 2010). More recently, two large multicenter 
studies evaluating the clinical outcome of ICD therapy in pediatrics and adults with 
congenital heart disease, including more than 200 children were published (Berul et al., 
2008; Von Bergen et al., 2011). These studies have similar results, showing that ICD therapy 
in children appears to be effective, but with a higher rate of inappropriate shock therapy 
and complications as compared with adult series. The growing number of ICD 
implantations in children has now been followed by a decrease in the number of 
complications (Burns et al., 2011). Despite the lack of large randomized trials, efforts have 
been made to develop guidelines for ICD therapy in children. Recommendations for ICD 
therapy in primary and secondary prevention of SCD in adults have been formalized in the 
2006 ACC/AHA guidelines (Zipes et al., 2006). Class I indications in pediatric and 
congenital heart disease (CHD) patients include aborted SCD without reversible cause. 
Sustained ventricular tachycardia (VT) associated with structural heart disease may be an 
ICD indication if not amenable to ablation or surgical resection (Blom 2008; Berul 2009; 
Zipes et al., 2006). In the following we will discuss the role of ICD treatment in children and 
young adults within different disease entities with an increased risk of SCD: 1) primary 
electrical heart disease; 2) cardiomyopathy, either hypertrophic or dilated; 3) operated or 
unoperated congenital heart disease. Finally, we will discuss the effect of ICD therapy on 
the quality of life and the different modalities of programming and implantation. 
2. Primary electrical heart disease 
Among the various disorders, presently known as primary electrical heart disease, the long-
QT syndrome is by far the most prevalent among young patients. The congenital long-QT  
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syndrome (LQTS) is a genetic channelopathy with variable penetrance and characterized by 
prolongation of the QT interval on the electrocardiogram. It is associated with increased 
propensity for polymorphic ventricular tachy-arrhythmias and SCD in young individuals 
with normal cardiac morphology (Goldenberg et al., 2010). To date, more than 500 
mutations have been identified in 12 LQTS genotypes, with the LQTS type 1 (LQT1) and 
LQTS type 2 (LQT2) genotypes accounting for nearly 90% of identified cases. Although 
there is a continuous growth in the number of ICDs used to prevent fatal outcome 
associated with life-threatening arrhythmic episodes in LQTS patients the identification of 
patients that will profit most of ICD implantation remains a challenge. Long QT syndrome 
without symptoms is increasingly recognized as family members are screened. It has, 
however, been studied that the risk of death does not increase by the death of a sibling 
(Kaufman et al., 2008) It is, therefore, important that the decision to implant a defibrillator is 
based on the own risk factors of an LQTS patient (Kaufman et al., 2008). Previous studies of 
highly symptomatic patients were more worrisome. In the era of genetic testing and device 
implantation, overall mortality is low with treatment. Device therapy, although effective, is 
not without complications and should be reserved for high-risk patients (Etheridge et al., 
2007). 
The first-line treatment of patients with LQTS remains the use of beta-blockers. These have 
been shown to be very effective especially in LQT1 and LQT2 patients in the prevention of 
cardiovascular events. However, in large studies a substantial number of LQTS patients 
were not treated by beta-blockers before ICD implantation. (Goldenberg et al., 2010). In 
high-risk patients beta-blockers reduce the risk of adverse events by about 70% (Goldenberg 
et al., 2010). These findings underscore the fact that beta-blocker therapy should be routinely 
administered  in all high risk LQT1 and LQT2 patients without contraindications as a first 
line measure (Goldenberg et al., 2010). Patients with syncope during beta-blocker therapy 
are at high risk of life-threatening events, and ICD therapy should be considered in these 
patients. The risk of beta-blocker failure is highest in young children and in women (Jons et 
al., 2010).  
There is a continuous growth in the number of ICDs in this patient group (Schwartz & 
Crotti 2008). Potentially, life-saving therapies were rendered at a 5% to 6% per year rate 
among those selected for ICD therapy. Similar inappropriate shock frequencies were also 
noted. Secondary prevention, genotype, and QTc predicted those most likely to receive 
appropriate therapy. In a recent study about ICD implantations in LQTS patients 
Schwartz et al showed that especially among the LQT3 subtype many patients were 
asymptomatic before ICD implantation, and probably did not need one (Schwartz et al., 
2010). They showed that some patients in whom an ICD was implanted the supposed high 
risk was questionable. Although the ICD implant frequency is greatest among LQT3 
patients, the greatest save rate has occurred among LQT2 women who were assessed to be 
at high risk (Horner et al., 2010). 
However, when used in a high-risk LQTS population, ICD therapy seems to be a safe option 
(Monnig et al., 2005). Risk factors for appropriate ICD shocks are longer QTc intervals and 
being survivors of a cardiac arrest. However, betablockers should always be added to ICD 
therapy, while some patients might benefit from additional antibradycardia pacing, 
prolonged detection time, and a rate-smoothing algorithm to prevent recurrent episodes 
(Monnig et al., 2005). 
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Fig. 1. Electrocardiogram of a 20-year old woman with the long-QT syndrome. A 
prolongation of the QT-interval of 520 msec is shown (normally less than 440 msec). 
3. Hypertrophic cardiomyopathy 
ICDs have proven effective in preventing SCD in young hypertrophic cardiomyopathy 
(HCM) patients with appropriate intervention rates of 11% for secondary and 4% for 
primary prevention, despite massive left ventricular (LV) hypertrophy, LV outflow 
obstruction, diastolic dysfunction or microvascular ischemia. Targeting candidates for 
prophylactic ICD therapy can be complex, compounded by the unpredictability of the 
arrhythmogenic substrate, the absence of a dominant risk factor, and difficulty in 
assembling randomized trials. However, a single major risk factor is often sufficient to 
justify an ICD, although additional markers and other disease features can resolve 
ambiguous decision-making. Nevertheless, the absence of all risk factors does not convey 
absolute immunity to SCD. However, when presenting with a normal electrocardiogram the 
patients seem at lower risk for cardiac events (McLeod et al., 2009). 
Until now, there is, however, no consensus as to the indication for primary prevention 
with ICD implantation in children (Ostman-Smith 2010). Especially a high rate of 
inappropriate shocks up to 27% and a complication rate up to 17% necessitate careful 
considerations when an ICD implantation is to be planned in the pediatric age group 
(Ostman-Smith 2010). 
The primary prevention risk factors in HCM are 1) family history of HCM related SCDs. 
When a high risk population that received primary prevention with ICD implantation was 
studied the number of appropriate shocks during follow-up did not differ between those 
with a family history of HCM related SCD, whether as an isolated risk factor or combined 
with other risk factors (Bos et al., 2010); 2) episodes of unexplained, recent syncope; 3) 
massive LV hypertrophy >30 mm; 4) nonsustained VT on ambulatory 24-hour Holter ECGs; 
www.intechopen.com
 Cardiac Defibrillation – Mechanisms, Challenges and Implications 
 
170 
5) hypotensive or attenuated blood pressure response to exercise (Maron 2010). In addition, 
Gimeno et al recently showed that ventricular arrhythmias during exercise increased the 
risk of SCD as well (Gimeno et al., 2009). However, patients who survive cardiac arrest may 
remain asymptomatic for prolonged periods after the first cardiac event, underscoring the 
unpredictability of the arrhythmogenic substrate in these patients. 
 
 
Fig. 2. Short axis of the left ventricle by echocardiography of a 14-year old boy with 
hypertrophic cardiomyopathy. There is a thickness of 30 mm (normally less than 11 mm). 
In children, the risk of non-sudden cardiac death is as high as sudden cardiac death. 
Extreme left ventricular hypertrophy and a blunted blood pressure response to exercise are 
risk factors (Decker et al., 2009). Risk factors for SCD are extreme left ventricular 
hypertrophy on the electrocardiogram and a septal thickness over 190% of normal, with a 
sensitivity of 91% and a specificity of 78% (Ostman-Smith et al., 2005). Children may be at 
risk for SCD already at young age, and should therefore be screened early in hypertrophic 
cardiomyopathy families  (Ostman-Smith et al., 2008).  
When evaluating HCM patients who underwent ICD placement the number of 
complications is considerable (Lin et al., 2009). In the study of Lin et al 181 patients with a 
mean age of 44 years were investigated. During a follow-up period of 5 years, 65 patients 
(36%) had a total of 88 device related complications including 42 (23%) patients with 
inappropriate shocks. Younger age and atrial fibrillation were associated with an increased 
risk of inappropriate ICD discharges. It is concluded that the high incidence of 
complications should be taken into account when considering ICD implantation in a high-
risk HCM patient (Lin et al., 2009). 
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4. Congenital heart disease 
Although most patients who are being operated for their congenital heart disease presently 
survive their surgery and lead a relatively normal life, a substantial portion of patients 
develop symptoms of heart failure or rhythm abnormalities in due time.  In adult patients 
with ischemic or non-ischemic cardiomyopathy an LV ejection fraction below 30% is 
considered a clear indication for primary prevention with ICD implantation (Moss et al., 
2002; Bardy et al., 2005). Risk stratification for primary prevention remains highly complex 
and is usually individualized, based on a variety of surgical, hemodynamic, 
electrocardiographic, and electrophysiologic factors (McLeod et al., 2010). However, some 
authors advocate that also for patients with congenital heart disease an LV ejection fraction 
below 30% as single risk factor is sufficient reason to implant an ICD (Silka & Bar-Cohen 
2008), which is argued by others (Triedman 2008). Since the overall rate of SCD is 5 to 10 
times lower than that observed in high-risk cardiomyopathy patients, the life expectancy in 
CHD patients is much larger. Furthermore, in CHD patients vascular access is often 
difficult, and the rate of device associated cardiac events and lead-failure is much higher, 
and they have variable cardiac anatomy. Therefore, the results of the large ICD trials cannot 
simply be extrapolated to the population of CHD patients. Other risk factors have to be 
taken into account before deciding to implant an ICD (Triedman 2008).  With the increasing 
knowledge of rhythm abnormalities in congenital heart disease and the emergence of 
interventional electrophysiologic techniques some ventricular arrhythmias can be treated by 
catheter ablation (Walsh 2007). ICD implantation remains to be limited to otherwise 
untreatable rhythm abnormalities. 
In a study of Yap et al more than 60% of the patients with an ICD and a congenital heart 
disease had a tetralogy of Fallot (Yap et al.,. 2007). However, the overall complication rate 
in the Fallot patients was higher as compared to other congenital heart defects, the 
number of inappropriate shocks was high (40%), while the number of appropriate shocks 
was low as compared to other patients (18% versus 33%). When compared with an older 
ICD population with dilated cardiomyopathy (DCM), the Tetralogy of Fallot patients 
were more likely to have experienced oversensing (45 vs. 13%; P < 0.02), inappropriate 
anti-tachycardia pacing delivery (20 vs. 2%; P < 0.05), and inappropriate cardioversion (25 
vs. 4%; P = 0.06) and less likely to receive appropriate therapies (Witte et al., 2008). On the 
other hand, Khairy et al studied 121 Fallot patients who received an ICD for primary 
(N=68) or secondary (N=53) prevention. During follow-up the number of appropriate 
shocks was considerable (30% of patients). This was, however, at the cost of a 5.8% yearly 
incidence of inappropriate shocks, and the occurrence of complications in 36 patients, 
mostly (70%) lead-related (Khairy et al., 2008). In Fallot patients with unstable ventricular 
tachycardia, their rhythm abnormalities may in some patients be treated by catheter 
ablation (Kriebel et al., 2007). 
5. ICD programming 
In children with ICDs, the risk of inappropriate shock therapy is significantly higher as 
compared to adult studies. Pediatric ICD series with mean intervals of follow-up between 29 
and 51 months have reported 20% to 50% inappropriate shock therapy. These shocks may 
have a negative impact on the quality of life, and can induce secondary arrhythmias.  
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Number 15 22 8 8 
Age (yr) 12.5 8.9 0.3-8 1-29 
Weight (kg) 36.5 25.5 4-29  
Follow-up (mo) 22 29 14.5 22 
Appr Shocks 4 7 2 2 
Inappr Shocks 3 4 0 3 
Revision 4 7 2 3 
Table 1. Outcomes of extracardiac ICD implantations in young patients and patients with 
congenital heart disease. Results are comparable to transvenous approaches. 
Inappropriate shocks in children are mostly caused by sinus tachycardia or supraventricular 
tachycardia. High sinus rates up to 200 per minute are not uncommon in children and 
patients with congenital heart disease have a high incidence of atrial arrhythmias, mostly 
intraatrial reentrant tachycardia. Implantation of a dual chamber ICD system can potentially 
reduce the incidence of inappropriate discharges attributable to the misclassification of sinus 
tachycardia or supraventricular tachycardia as a ventricular event. In a recent multicenter 
study the difference of appropriate and inappropriate shocks in a single chamber or dual 
chamber device in patients <30 years old was investigated (Lawrence et al., 2009). The 
authors found no differences between single chamber or dual chamber systems regarding 
the occurrence of appropriate or inappropriate shocks, irrespective of underlying 
cardiovascular disorder or type of ICD system. (Lawrence et al., 2009). T-wave sensing is 
another important cause of inappropriate shock therapy especially in the group of patients 
with long QT syndrome. Exercise tests are required to obtain maximal heart rate and to 
evaluate T wave sensing during high heart rates. QRS discrimination or atrial discrimination 
algorithms can be helpful tools to prevent some of these problems. β-blockade can also be a 
practical therapy to avoid inappropriate ICD shock for supraventricular tachycardias or 
sinus tachycardia. However, the most important measure to reduce inappropriate shocks is 
careful ICD programming of the individual child with regard to detection rate and time 
immediately after ICD implantation. In a recent article several programming tips have been 
given (Khairy & Mansour 2011). Since sinus tachycardia and supraventricular tachycardia 
may have frequencies as high as 200 bpm, most young patients have a ventricular 
fibrillation zone programmed up to 220 bpm. Concerning detection times there is a 
compromise between overtreating otherwise self-terminating events and delaying therapy 
for potentially unstable arrhythmias. Detection times as long as 18 of 24 intervals or even 30 
of 40 intervals have been advocated with no increase in adverse events. Antitachycardia 
pacing (ATP) has been shown to be effective in the majority of congenital heart disease 
patients, thereby lowering the number of shocks. 
Although routine testing of the defibrillation threshold (DFT) is not necessary during 
follow-up of pediatric ICD patients, any clinical change or problem should be evaluated 
immediately and DFT testing should also be considered in this situation. (Theuns & Gold, 
2010). In young children with subcutaneous ICD systems regular DFT testing should be 
considered during growth. 
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There seem to be differences in the frequency of ICD-related complications between children 
and adults. However, due to the small number of patients in pediatric series it is difficult to 
estimate the true incidence of ICD related complications in children. (Shah et al., 2009). 
Implantation procedure-related complications include pocket infection, pocket hematoma, 
microdislodgement requiring lead manipulation , hemothorax, superior vena cava 
syndrome, pneumonia, electromechanical dissociation requiring cardiopulmonary 
resuscitation and second degree burns from repeated external rescue shocks (Shah et al., 
2009). Especially the number of infections seem to be higher in children as compared to 
adults (Link et al., 1999). The most common ICD system related adverse effect is the high 
incidence of inappropriate shocks and a high incidence of lead failures in children. 
Inappropriate shocks are usually related to the occurrence of sinus tachycardia, 
supraventricular tachycardia, T wave oversensing or QRS complex double sensing. Lead 
failures are strongly related to the size of the patient. The youngest and smallest patients 
have the highest risk of lead complications. Furthermore, higher levels of exercise and 
activity in the pediatric population may increase the amount of lead problems.  
7. Mode of ICD implantation 
In children or young patients with congenital heart defects it is often not possible to make 
use of routine transvenous ICD systems. Underlying causes are the size of the patient or 
structural heart diseases with residual intracardiac shunts and abnormal systemic venous 
pathways. Various modifications have been used to implant ICDs in patients with limited 
venous access (Cannon et al., 2006; Bove et al., 2010; Greene et al., 2004; Kriebel et al., 
2006; Stephenson et al., 2006; Tomaske et al., 2008). These include subcutaneous patches, 
epicardial and pleural lead positioning, use of the subxiphoid incision, or direct 
transatrial approach. It is important that the technique used is individualized in the 
diverse population of children and young patients with congenital heart disease in need 
for ICD placement (Stephenson et al., 2006). Recently,  Radbill et al compared the use of 
transvenous ICDs with nontransvenous systems in a group of pediatric and congenital 
heart disease patients  (Radbill et al., 2010). Although no differences were reported 
considering appropriate or inappropriate shocks there was a significantly higher amount 
of ICD system failure in the nontransvenous group. System survival at 12, 24, and 36 
months was 73%, 55% and 49% in the nontransvenous group compared to 91%, 83% and 
76% in the transvenous group. Causes of system failure in the nontransvenous group 
included pace-sense lead failure, shock coil failure, generator migration, and loosened set-
screw connection. 
Recently, the search for avoidance of transvenous lead placement has resulted in the 
development of an entirely subcutaneous ICD system (Bardy et al., 2010). The system 
consists of a parasternal electrode and a left lateral thoracic pulse generator. In a trial of 55 
adult patients it was shown as effective in terminating ventricular tachyarrhythmias with 
little complications  during a 10-month follow-up period. This subcutaneous ICD system can 
also be used in older children and has been reported in two children of 10 and 12 years old 
(34 and 35 kg body weight) (McLeod and McLean 2010). In both children this device was 
implanted without complications, and no adverse events occurred during an 8- and 5-month 
follow-up period (McLeod & McLean 2010).  
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Fig. 3. Chest X-ray of a 6-month old child with an ICD. The active can is placed abdominally, 
and the pacing wires are placed epicardially. A subcutaneous patch is in use for eventual 
shocks. 
Another approach is the placement of the ICD in the axilla. The usual infraclavicular 
placement of a transvenous ICD can cause a quite visible scar with a suboptimal cosmetic 
result. Furthermore, straps can rub and cause irritation at this site (Collins et al., 2009; 
Rausch et al., 2010). In a large retrospective review it was shown that there were no 
differences between the axillary and infraclavicular technique in implant characteristics, 
lead longevity, implant complications, lead fractures or dislodgements, inappropriate ICD 
discharges, or device infections (Rausch et al., 2010). 
8. Home monitoring 
Since 2000 a remote control system was introduced for the follow-up of ICD patients. 
Through this system data from the implanted device are transmitted  to a website once a 
day as well as immediately following an arrhythmia. By this method changes in ICD 
function, lead problems, and asymptomatic arrhythmias can be detected earlier without the 
patient actually visiting the hospital. It has been shown that the events as send by the home 
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monitoring system show excellent comparability to the data as obtained by standard clinical 
evaluation (Perings et al., 2011). The home monitoring system can detect several, otherwise 
asymptomatic episodes enhancing prompt detection of for instance lead problems and 
facilitates management decisions (Varma et al., 2010). Most patients show a high level of 
acceptance and satisfaction of this new system after a mean follow-up period of 1 year, with 
only some refusing the home monitoring (Ricci et al., 2010). Until now, however, this system 
has mostly been used in the adult population, and data about the appropriateness in 
pediatrics are as yet lacking.  
9. Quality of life 
With the increasing number of ICDs in young patients the psychological effects has been 
studied as early as 1996 (Dubin et al., 1996). Nearly 75% of the patients felt their health was 
good to excellent with 40% reporting improvement since ICD implantation. All felt capable 
of performing daily activities (Dubin et al., 1996).  
The implantation of an ICD has a great impact on the quality of life of these patients. These 
psychological effects have sofar been investigated by many authors (Herrmann et al., 1997). 
The poor psychosocial outcome in these patients may be related to the underlying 
cardiovascular condition (Burke et al., 2003), or it may be the effect of surviving an out of 
hospital cardiac arrest, not related to the treatment received (Kamphuis et al., 2002). It has 
been found that the lasting psychological distress will not dissipate spontaneously or 
naturally and that psychosocial intervention may be warranted (Kamphuis et al., 2003). The 
most common psychological problems are depression and anxiety. Depressive symptoms 
persist over time, and are associated with a higher incidence of shock therapy (Suzuki et al., 
2010). However, concerns about the ICD has been found a predictor of psychological 
morbidity independently of the number of shocks (Pedersen et al., 2005). On the other hand, 
Luyster et al found no relation between number of shocks and anxiety (Luyster et al., 2006). 
They found especially a higher level of perceived resource loss to be associated with higher 
levels of both anxiety and depression (Luyster et al., 2006). 
The growing pediatric ICD population stresses the need to evaluate the quality of life in 
this group of ICD recipients. Adult patients with ICDs show significantly worse 
psychological and physical functioning. Behavioral changes have been reported such as 
reduced activity, avoidance, depression, and anxiety, especially in those who had received 
ICD shocks. These finding in adults could not be confirmed in a recent study in a group of 
pediatric ICD recipients. In this study, cardiac illness severity and ICD shock therapy 
were not significantly associated with anxiety, depression, quality of life, or family 
functioning. 
Recently, we have also evaluated health-related quality of life study in 30 Dutch pediatric 
ICD recipients using different quality of life questionnaires. This study showed that 
pediatric ICD recipients showed more problems in the domains of motor functioning, sleep, 
work/school, negative emotions, and anxiety. Furthermore, worry and anxiety were 
significantly associated with the number of ICD shocks (unpublished data). These findings 
indicate that avoidance or reduction of inappropriate shocks is one of the most important 
steps to improve quality of life. Furthermore, it emphasizes the need of proper guidance 
and, if necessary, implementation of psychological interventions. Screening for 
cardiovascular diseases may have its own impact, Children who were genetically tested 
carriers showed to have a reduced psychological well-being (Smets et al., 2008). 
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Fig. 4. An ICD strip of an appropriate shock is shown. Fast ventricular tachycardia is 
followed by a 21-J shock which terminated the tachycardia. This is followed by an escape 
rhythm with broad QRS complexes. 
10. Conclusions 
ICD implantations are increasingly performed in children and young adults with a variety 
of underlying cardiac disorders. Although the effectiveness of ICD therapy in this specific 
population is good, there are concerns about the high number of inappropriate shocks and 
lead problems. New developments include the complete subcutaneous device and home 
monitoring systems. Although the overall quality of life usually is good, several patients 
need psychological support, and this support has to be included in regular follow-up 
programs. 
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